The first project is currently filed and pending FDA approval. The companies plan to file an abbreviated new drug application (ANDA) with the FDA for the second product in the third Quarter of 2008.
Upon approval by the FDA, both products will be supplied by Orit Laboratories, and will be marketed and distributed by Breckenridge Pharmaceutical, exclusively in the US.